1. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
   Jiao Yang et al, 2016, Tumor Biol. CrossRef
2. Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.
   Ingrid Garajová et al, 2017, Int J Mol Sci CrossRef
3. High concentration of miR-133 is a useful marker for the diagnosis of lymphoma- associated hemophagocytic syndrome
   Wuping Li et al, 2017, CBM CrossRef
4. MicroRNAs in cancer drug resistance: Basic evidence and clinical applications
   Mehri Ghasabi et al, 2018, J Cell Physiol CrossRef
5. MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth
   Jin-Feng Zhu et al, 2018, Cancer Cell Int CrossRef
6. miRNAs as Modulators of EGFR Therapy in Colorectal Cancer
   Diane M. Pereira et al, 2018 CrossRef
7. Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies
   Madhav Madurantakam Royam et al, 2019, Mol Diagn Ther CrossRef
8. Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics
   Svetlana Miroshnichenko et al, 2019, Front. Pharmacol. CrossRef
9. The lncRNA EGFR-AS1 is linked to migration, invasion and apoptosis in glioma cells by targeting miR-133b/RACK1.
   Zhi-Qiang Dong et al, 2019, Biomed Pharmacother CrossRef
10. MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy
    Matthew Goblirsch et al, 2017, Pharmacogenomics CrossRef
11. Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
    Kenneth K.W. To et al, 2019, Expert Opinion on Drug Discovery CrossRef
12. miR-133b down-regulates ABCC1 and enhances the sensitivity of CRC to anti-tumor drugs
    Miao Chen et al, 2017, Oncotarget CrossRef
13. miR-133b, a particular member of myomiRs, coming into playing its unique pathological role in human cancer.
    Daojiang Li et al, 2017, Oncotarget CrossRef
14. Negative feedback between TAp63 and Mir-133b mediates colorectal cancer suppression
    Jing Dai et al, 2016, Oncotarget CrossRef
15. miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells
    Chen Lin et al, 2018, Int J Mol Med CrossRef
16. miRNA Clusters with Down-Regulated Expression in Human Colorectal Cancer and Their Regulation.
    Paulína Pidíkova et al, 2020, Int J Mol Sci CrossRef
17. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Charles M Bowen et al, 2021, Cancer Prev Res (Phila) CrossRef
18. Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer
    Jinjin Chu et al, 2022, Front. Oncol. CrossRef
19. Micro RNA differential expression profile in canine mammary gland tumor by Next Generation Sequencing
    Hui-Wen Chen et al, 2022, Gene CrossRef
20. miRNAs as cornerstones in colorectal cancer pathogenesis and resistance to therapy: A spotlight on signaling pathways interplay - A review.
    Mahmoud A Elrebehy et al, 2022, Int J Biol Macromol CrossRef
21. Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy
    Shanshan Wei et al, 2022, Cell Commun Signal CrossRef
22. miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targets
    Emiliya Nikolova et al, 2023, Non-coding RNA Research CrossRef
23. Platinum-Based Targeted Chemotherapies and Reversal of Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC)
    Hassaan Umar et al, 2024, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef
24. MicroRNA: Exploring Their Multifaceted Role in Cancer
    Nadia M. Hamdy et al, 2024 CrossRef
25. Plasma miR-122-5p and miR-142-5p and their role in chemoresistance of patients with colon cancer
    Klara Vokacova et al, 2024 CrossRef